Cargando…
Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285370/ https://www.ncbi.nlm.nih.gov/pubmed/34323013 http://dx.doi.org/10.1002/btpr.3192 |
_version_ | 1784747761270259712 |
---|---|
author | Diep, Jonathan Le, Huong Le, Kim Zasadzinska, Ewelina Tat, Jasmine Yam, Pheng Zastrow, Ryan Gomez, Natalia Stevens, Jennitte |
author_facet | Diep, Jonathan Le, Huong Le, Kim Zasadzinska, Ewelina Tat, Jasmine Yam, Pheng Zastrow, Ryan Gomez, Natalia Stevens, Jennitte |
author_sort | Diep, Jonathan |
collection | PubMed |
description | Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability. |
format | Online Article Text |
id | pubmed-9285370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92853702022-07-15 Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines Diep, Jonathan Le, Huong Le, Kim Zasadzinska, Ewelina Tat, Jasmine Yam, Pheng Zastrow, Ryan Gomez, Natalia Stevens, Jennitte Biotechnol Prog RESEARCH ARTICLES Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability. John Wiley & Sons, Inc. 2021-08-10 2021 /pmc/articles/PMC9285370/ /pubmed/34323013 http://dx.doi.org/10.1002/btpr.3192 Text en © 2021 Amgen Inc. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | RESEARCH ARTICLES Diep, Jonathan Le, Huong Le, Kim Zasadzinska, Ewelina Tat, Jasmine Yam, Pheng Zastrow, Ryan Gomez, Natalia Stevens, Jennitte Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title | Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title_full | Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title_fullStr | Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title_full_unstemmed | Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title_short | Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
title_sort | microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285370/ https://www.ncbi.nlm.nih.gov/pubmed/34323013 http://dx.doi.org/10.1002/btpr.3192 |
work_keys_str_mv | AT diepjonathan microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT lehuong microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT lekim microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT zasadzinskaewelina microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT tatjasmine microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT yampheng microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT zastrowryan microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT gomeznatalia microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines AT stevensjennitte microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines |